Ondansetron Stada

Ondansetron, the active ingredient in Ondansetron Stada, is a 5-HT3 receptor antagonist presented as an oral tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult patients.

GNH USA supplies Ondansetron Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Stada is used to control nausea and vomiting by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract.

Chemotherapy-induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting caused by cytotoxic drugs. Radiation-induced nausea and vomiting: prevents or lessens nausea and vomiting after therapeutic radiation exposure. Postoperative nausea and vomiting: helps maintain patient comfort and reduces the need for rescue antiemetics after surgery.

Ondansetron Stada may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often resolving without treatment. - Constipation: reduced bowel movements, may require dietary adjustments. - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or weak. - Diarrhoea: loose stools occurring shortly after dosing. - Abdominal discomfort: mild cramping or pain.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias, especially in patients with electrolyte disturbances. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic drugs, presenting with agitation, hyperthermia, and neuromuscular abnormalities. - Hepatic dysfunction: elevated liver enzymes in susceptible individuals. - Vision changes: blurred vision or visual disturbances. - Seizures: rare occurrence, particularly in patients with pre‑existing neurological conditions.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential risks.

Cardiac assessment: review history of arrhythmias or prolonged QT and correct electrolyte imbalances. Hepatic function: adjust use in patients with severe liver impairment. Drug hypersensitivity: avoid in individuals with known allergy to ondansetron or other 5‑HT3 antagonists. Pregnancy and lactation: consider risks versus benefits; data are limited. Concomitant serotonergic agents: monitor for signs of serotonin syndrome. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron Stada can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Apomorphine: co‑administration may cause severe hypotension and loss of consciousness. - Other QT‑prolonging drugs (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias. - Concurrent use of multiple 5‑HT3 antagonists: may lead to additive toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): monitor for serotonin syndrome. - Anticholinergic drugs: may enhance constipation risk. - Diuretics: watch for electrolyte disturbances that could exacerbate QT prolongation.